Building a Follow-On Business: $3 Billion Reasons to Love Biosimilars
This article was originally published in RPM Report
One Wall Street analyst thinks biosimilars could represent a $3 billion dollar business line for Amgen in less than a decade. Is that attractive enough to pursue a follow-on strategy for innovator companies? The answer is an unqualified yes.